USSN: 10/001,563

Attorney Docket No: 3087.00007

-2-

## **CLAIMS:**

1. (Currently amended) A method of augmenting transient protein synthesis in a cell by delivering, directly to the cell, mRNA encoding an <u>eukaryotic translation initiator</u> initiation factor functionally related to protein synthesis, thereby augmenting endogenous protein

synthesis.

2. (Currently amended) The method according to claim 1, wherein said delivering step includes intracellularly delivering the mRNA using a method selected from the group

consisting essentially of gene gun delivery, particle acceleration delivery, and topical

devliery delivery.

4. (Original) The method according to claim 1, wherein said delivering step includes

particle acceleration of the mRNA to the cell.

Please cancel.

7. (Currently amended) A method of augmenting transient protein synthesis in cells in

need of increased protein synthesis including the step of directly intracellularly delivering

mRNA encoding a translational regulatory protein functionally related to protein production

an activator of a eukaryotic translation initiator to increase protein synthesis from

endogenous <u>eukaryotic translation initiator</u> mRNA in the cells.

8. (Currently amended) The method according to claim 7, wherein said delivering step

further includes delivering mRNA encoding the eukaryotic translation initiator initiation

factors to increase protein synthesis.

USSN: 10/001,563

Attorney Docket No: 3087.00007

- 3 -

21. (Currently amended) A method of augmenting wound healing collagen synthesis

and tensile strength of wounds, including the steps of:

directly intracellularly delivering mRNA functionally related to protein production of a

eukaryotic translation initiator; and

potentiating an increase in protein synthesis from endogenous cellular mRNA in the

wound from the delivered mRNA.

22. (Currently amended) The method according to claim 21, wherein said potentiating

step includes potentiating the increase in protein synthesis of epidermal growth factors from

endogenous cellular mRNA in the wound from the delivered mRNA.

23. (Currently amended) The method according to claim 21, wherein said delivering

step further includes directly intracellularly delivering mRNA encoding a translational

regulatory protein an activator of the eukaryotic translation initiator to increase protein

synthesis from endogenous mRNA in the wound.

24. (Currently amended) The method according to claim 23 27, wherein said-delivering

step-further-includes directly intracellularly delivering mRNA-encoding the translation

initiation factor 4 is eIF4E to increase protein synthesis from endogenous mRNA in the

wound.

25. (New) The method according to claim 1, wherein the eukaryotic translation initiator

is a eukaryotic translation initiation factor 4.

26. (New) The method according to claims 7 or 8, wherein the eukaryotic translation

initiator is a eukaryotic translation initiation factor 4.

USSN: 10/001,563

Attorney Docket No: 3087.00007

27. (New) The method according to claim 21, wherein the eukaryotic translation initiator is a eukaryotic translation initiation factor 4.

-4-